The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of abiraterone, olaparib or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.
 
Zachery Reichert
No Relationships to Disclose
 
Benedito A. Carneiro
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb
 
Stephanie Daignault-Newton
Consulting or Advisory Role - Augmenix
Research Funding - Bayer
 
Amanda Sullivan
No Relationships to Disclose
 
Felix Yi-Chung Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Todd Matthew Morgan
Consulting or Advisory Role - MDxHealth; Myriad Genetics
Research Funding - GenomeDx (Inst); MDxHealth (Inst); Myriad Genetics (Inst)
 
Scott A. Tomlins
Leadership - Strata Oncology
Stock and Other Ownership Interests - Strata Oncology
Consulting or Advisory Role - Abbvie; Astellas Medivation; Janssen; Roche; Sanofi; Strata Oncology; Ventana Medical Systems
Research Funding - Astellas Medivation (Inst); Compendia Bioscience (Inst); GenomeDx (Inst); Life Technologies (Inst); Thermo Fisher Scientific (Inst)
Patents, Royalties, Other Intellectual Property - I am a coauthor on a patent issued to the University of Michigan on ETS gene fusions in prostate cancer. The diagnostic field of use has been licensed to Hologic/Gen-Probe Inc., who has sublicensed some rights to Ventana Medical Systems/Roche.
Travel, Accommodations, Expenses - Compendia Bioscience; Life Technologies; Strata Oncology; Thermo Fisher Scientific
 
Arul M. Chinnaiyan
Consulting or Advisory Role - Tempus
Patents, Royalties, Other Intellectual Property - GenomeDx; Hologic
 
Maha Hussain
Consulting or Advisory Role - Abbvie; Bayer; Genentech/Roche
Research Funding - Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Abbvie; Bayer; Genentech